Skip to main navigation Skip to search Skip to main content

International trends in clozapine use: a study in 17 countries

  • C. J. Bachmann*
  • , L. Aagaard
  • , M. Bernardo
  • , L. Brandt
  • , M. Cartabia
  • , A. Clavenna
  • , A. Coma Fusté
  • , K. Furu
  • , K. Garuoliené
  • , F. Hoffmann
  • , S. Hollingworth
  • , K. F. Huybrechts
  • , L. J. Kalverdijk
  • , K. Kawakami
  • , H. Kieler
  • , T. Kinoshita
  • , S. C. López
  • , J. E. Machado-Alba
  • , M. E. Machado-Duque
  • , M. Mahesri
  • P. S. Nishtala, D. Piovani, J. Reutfors, L. K. Saastamoinen, I. Sato, C. C.M. Schuiling-Veninga, Y. C. Shyu, D. Siskind, S. Skurtveit, H. Verdoux, L. J. Wang, C. Zara Yahni, H. Zoëga, D. Taylor
*Corresponding author for this work
  • Freelance Researcher
  • Life Science Team
  • University of Barcelona
  • Karolinska Institutet
  • IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica
  • Generalitat de Catalunya
  • Norwegian Institute of Public Health
  • National Health Insurance Fund of the Republic of Lithuania
  • Vilnius University
  • University of Oldenburg
  • University of Queensland
  • Brigham and Women’s Hospital
  • University of Groningen
  • Kyoto University
  • Universidad Tecnológica de Pereira
  • University of Otago
  • The Social Insurance Institution
  • Chang Gung Memorial Hospital
  • Academia Sinica - Institute of Molecular Biology
  • Chang Gung University of Science and Technology
  • Université de Bordeaux
  • South London and Maudsley NHS Foundation Trust
  • King's College London

Research output: Contribution to journalJournal Article peer-review

274 Scopus citations

Abstract

Objective: There is some evidence that clozapine is significantly underutilised. Also, clozapine use is thought to vary by country, but so far no international study has assessed trends in clozapine prescribing. Therefore, this study aimed to assess clozapine use trends on an international scale, using standardised criteria for data analysis. Method: A repeated cross-sectional design was applied to data extracts (2005–2014) from 17 countries worldwide. Results: In 2014, overall clozapine use prevalence was greatest in Finland (189.2/100 000 persons) and in New Zealand (116.3/100 000), and lowest in the Japanese cohort (0.6/100 000), and in the privately insured US cohort (14.0/100 000). From 2005 to 2014, clozapine use increased in almost all studied countries (relative increase: 7.8–197.2%). In most countries, clozapine use was highest in 40–59-year-olds (range: 0.6/100 000 (Japan) to 344.8/100 000 (Finland)). In youths (10–19 years), clozapine use was highest in Finland (24.7/100 000) and in the publicly insured US cohort (15.5/100 000). Conclusion: While clozapine use has increased in most studied countries over recent years, clozapine is still underutilised in many countries, with clozapine utilisation patterns differing significantly between countries. Future research should address the implementation of interventions designed to facilitate increased clozapine utilisation.

Original languageEnglish
Pages (from-to)37-51
Number of pages15
JournalActa Psychiatrica Scandinavica
Volume136
Issue number1
DOIs
StatePublished - 07 2017

Bibliographical note

Publisher Copyright:
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Keywords

  • clozapine
  • pharmacoepidemiology
  • psychotic disorders

Fingerprint

Dive into the research topics of 'International trends in clozapine use: a study in 17 countries'. Together they form a unique fingerprint.

Cite this